Incidence Rates and Adjusted Hazard Ratios of Developing Hepatocellular Carcinoma (HCC) by Risk Predictors in 1,822 Anti-HCV-Seronegative Chronic HBV Carriers.

+: Using the quartile of each seromarker as the cut-off point except AAR.*: Age, gender, and study townships were included in Cox proportional hazards models.Abbreviation: HCC, hepatocellular carcinoma; HBeAg, hepatitis B e antigen; Anti-HCV, antibodies against hepatitis C virus; HBV, hepatitis B virus; AST, aspartate aminotransferase; ALT, alanine aminotransferase; AAR, AST/ALT ratio; AFP, alpha-fetoprotein; GGT, gamma-glutamyltransferase.+: 除天冬氨酸转氨酶/丙氨酸转氨酶比值（AST/ALT ratio, AAR）外，以各项血清标志物的四分位数作为截断切点。 *: 将年龄、性别及研究涉及的乡镇纳入Cox比例风险回归模型。 缩写：肝细胞癌（hepatocellular carcinoma, HCC）；乙型肝炎e抗原（hepatitis B e antigen, HBeAg）；抗丙型肝炎病毒抗体（antibodies against hepatitis C virus, Anti-HCV）；乙型肝炎病毒（hepatitis B virus, HBV）；天冬氨酸转氨酶（aspartate aminotransferase, AST）；丙氨酸转氨酶（alanine aminotransferase, ALT）；天冬氨酸转氨酶/丙氨酸转氨酶比值（AST/ALT ratio, AAR）；甲胎蛋白（alpha-fetoprotein, AFP）；γ-谷氨酰转移酶（gamma-glutamyltransferase, GGT）。